Foxiga Korea Local Phase 4 Study

PHASE4CompletedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

January 5, 2016

Primary Completion Date

January 15, 2018

Study Completion Date

January 15, 2018

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Dapagliflozin

Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment

DRUG

Glimepiride

Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment

Trial Locations (14)

10326

Research Site, Goyang-si

11765

Research Site, Uijeongbu-si

13620

Research Site, Seongnam-si

15355

Research Site, Ansan-si

16499

Research Site, Suwon

21565

Research Site, Incheon

35233

Research Site, Daejeon

41931

Research Site, Daegu

51353

Research Site, Changwon-si

01830

Research Site, Seoul

04401

Research Site, Seoul

05278

Research Site, Seoul

06273

Research Site, Seoul

220-701

Research Site, Wŏnju

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY